Abstract
CD10 is a cell surface zinc-dependent endopeptidase, which degrades many bioactive peptides. CD10 expression in tumour stroma is associated with biological aggressiveness of many epithelial malignancies. To date, only one study has correlated with expression of CD10 with well-known prognostic markers of breast, that is, ER, PR, HER2-neu, and tumour grade; however, its correlation with ki67 is still not studied. The aim of this study is to evaluate stromal CD10 expression in breast carcinoma and to examine its correlation with ER, PR, HER2-neu, and Ki67. Methods and Results. CD10 expression in fifty patients was assessed by immunohistochemistry and scored as negative, weak and strong. CD10 was found to be positive in stroma of 40/50 (80%) cases. Stromal CD10 showed positive correlation with tumour grade, HER2-neu (P = .000), and ki67 (P = .027), negative correlation with ER and PR. Conclusions. Hence CD10 expression correlated strongly with well-established negative prognostic markers, that is, HER2-neu and ki67 positivity, ER/PR negativity, and higher tumour grade, thus indicating that CD10 can be used as independent marker indicating poor prognosis and can be used as target for the development of novel therapies.
Highlights
Breast cancer is one of the commonest cancers among women globally
A better understanding of stromal contribution to cancer progression will identify specific signals that promote growth, dedifferentiation, invasion, and ectopic survival of tumour cells and eventually result in the identification of new therapeutic targets for future treatment [1]. This justifies the study of new stromal marker CD10 in the prognosis of invasive breast carcinoma
CD10 immunostaining was done on all 50 cases
Summary
Breast cancer is one of the commonest cancers among women globally. Each individual tumour varies with respect to invasive and metastatic potential as well as growth rate. Various markers have been used to study the oncogene expression or amplification. Stromal markers are emerging as novel markers in assessing the prognosis of invasive breast cancer and have not been studied extensively till date. A better understanding of stromal contribution to cancer progression will identify specific signals that promote growth, dedifferentiation, invasion, and ectopic survival of tumour cells and eventually result in the identification of new therapeutic targets for future treatment [1]. This justifies the study of new stromal marker CD10 in the prognosis of invasive breast carcinoma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
